Vasoactive Agents in Cardiogenic Shock
Definition
Vasoactive drugs — vasopressors, inotropes, and inodilators — are used in CS to restore perfusion pressure, augment cardiac output, or reduce systemic vascular resistance. No vasoactive agent has demonstrated a mortality benefit in CS RCTs. Use the lowest dose for the shortest duration.
Key Concepts
General Principles
- Goal: MAP >60–65 mmHg; ongoing RCT testing 55 vs 65 mmHg target — lower MAP may reduce LV afterload but risks organ hypoperfusion sources/cardiogenic-shock-nejm-2026 (very high)
- No mortality-reducing inotrope or vasopressor established (Cochrane systematic review) sources/cardiogenic-shock-acc-2025 (very high)
- Use lowest possible dose for shortest possible duration to avoid tachyarrhythmias, ischemia, and catecholamine toxicity
- Address congestion in parallel: IV loop diuretics → thiazide augmentation → ultrafiltration/RRT
Vasopressors
Norepinephrine — first-line
- Reasonable first-choice for most hypotensive CS patients sources/cardiogenic-shock-acc-2025 (very high)
- Combined alpha- and beta-adrenergic activity maintains BP without excessive tachycardia
Dopamine — caution
- Dopamine vs norepinephrine (n=1,679): dopamine → substantially more arrhythmic events; no mortality difference sources/cardiogenic-shock-nejm-2026 (very high)
- Avoid as first-line vasopressor in CS given arrhythmia risk
Epinephrine — inferior metabolic profile
- Epinephrine vs norepinephrine: similar cardiac index but epinephrine → worse heart rate and lactic acidosis sources/cardiogenic-shock-nejm-2026 (very high)
- Use with caution; lactic acidosis can confound clinical monitoring in CS
Phenylephrine (pure vasopressor) — discouraged
- Pure vasopressors as first-line are strongly discouraged: reflex bradycardia reduces cardiac output and worsens tissue perfusion sources/cardiogenic-shock-acc-2025 (very high)
Inotropes
Dobutamine vs Milrinone
- DOREMI trial: no difference in primary composite endpoint sources/cardiogenic-shock-acc-2025 (very high)
- Milrinone caution: renally cleared; long half-life — use with caution in worsening renal function
- No inotrope established as superior for mortality
Inodilators / Vasodilators
- Consider in normotensive CS with elevated SVR (high-afterload phenotype); reduce SVR to augment CO without raising BP further
- Under ECPELLA: adding a vasodilator (reducing SVR) markedly reduces PVA (myocardial O2 consumption) and increases total system flow — the "total unloading" condition sources/mcs-jic-2023 (high)
Levosimendan — calcium sensitiser + KATP channel activator + mitochondrial cardioprotective agent
- Triple mechanism: (1) binds cTnC in calcium-dependent manner → enhanced contractility without raising intracellular calcium or O₂ consumption; (2) opens KATP channels in vascular smooth muscle → arterial/venous/pulmonary vasodilation; (3) mitochondrial KATP channel opening → prevents mPTP → anti-apoptotic; endothelial NO via p38 MAPK also contributes to vasodilation; PDE3 inhibition only at supratherapeutic doses sources/levosimendan-drugs-2001 (medium) sources/levosimendan-ecr-2024 (medium)
- Only inotrope with zero myocardial oxygen consumption increase — uniquely contrasts with all other vasoactive agents sources/levosimendan-ecr-2024 (medium)
- Does NOT increase intracellular cAMP or calcium; ventricular arrhythmia risk lower than catecholamines (0% VF vs dobutamine 83% VT/33% VF in animal models); AF risk increased vs dobutamine and placebo; VT signal discordant: REVIVE higher vs placebo, SURVIVE similar vs dobutamine sources/levosimendan-drugs-2001 (medium) sources/levosimendan-jcm-2022 (high) sources/levosimendan-ecr-2024 (medium)
- Hypothermia safety: does NOT increase action potential triangulation at 26°C (milrinone/isoprenaline do) → potentially safer inotrope in hypothermic patients sources/levosimendan-ecr-2024 (medium)
- Key CS trials: LIDO 180-day HR 0.57 (p=0.029); enoximone vs levosimendan in refractory CS/AMI: survival 69% vs 37% (p=0.023) sources/levosimendan-ecr-2024 (medium)
- VA-ECMO weaning: MIXED evidence — multiple studies positive; one cohort (n=200) negative; dedicated weaning RCT FAILED primary endpoint sources/levosimendan-ecr-2024 (medium) sources/cardiogenic-shock-nejm-2026 (very high); temporary VAD adjuvant: improved weaning rate + lower 6-month mortality
- Special populations: PPCM — preferred over dobutamine (teratogenicity contraindication); Takotsubo — LV recovery occurred only in levosimendan group vs dobutamine in one comparative study; cardiac surgery — reduces LCOS and MCS need vs placebo/dobutamine/milrinone; septic shock — multiple meta-analyses suggest mortality reduction sources/levosimendan-ecr-2024 (medium)
- Dosing threshold: monotherapy only when SBP >90 mmHg; below → combine with vasopressors; levosimendan + dobutamine combination evidence supports complementary synergy sources/levosimendan-ecr-2024 (medium)
- Active metabolite OR-1896 t½ ≈70–80h → pharmacodynamic effects ≥1 week after infusion
- See entities/Levosimendan for full mechanistic and trial detail
Contraindicated in Active CS
- β-blockers and RAAS inhibitors: do NOT initiate or continue in active CS
- Resume only after hemodynamically stable for ≥24 hours off all vasopressors and inotropes sources/cardiogenic-shock-aha-2017 (high)
- Premature resumption risks hemodynamic collapse
Summary Comparison Table
| Agent | Class | Key Data | Caution |
|---|---|---|---|
| Norepinephrine | Vasopressor | First-line; balanced profile | — |
| Dopamine | Vasopressor/inotrope | More arrhythmias vs NE (n=1,679) | Avoid as first-line |
| Epinephrine | Vasopressor/inotrope | Similar CI vs NE; worse HR + lactic acidosis | Metabolic confound |
| Phenylephrine | Pure vasopressor | Reflex bradycardia reduces CO | Strongly discouraged |
| Dobutamine | Inotrope | = Milrinone (DOREMI) | Tachyarrhythmia |
| Milrinone | Inodilator | = Dobutamine (DOREMI) | Renal clearance |
| Levosimendan | Inodilator/Ca²⁺ sensitiser | Failed VA-ECMO weaning RCT; zero O₂ cost; enoximone survival 69% vs 37% (CS/AMI); PPCM/takotsubo preferred | SBP >90 for monotherapy; VT signal discordant (REVIVE/SURVIVE) |
| β-blockers | — | Contraindicated in active CS | Hemodynamic collapse |
Contradictions / Open Questions
- No mortality-reducing agent: despite widespread use, no inotrope or vasopressor reduces mortality in CS RCTs (Cochrane); practice varies widely between centers sources/cardiogenic-shock-acc-2025 (very high)
- Optimal MAP target: 55 vs 65 mmHg RCT ongoing — lower target may reduce LV afterload and tMCS burden but the safety threshold is unknown sources/cardiogenic-shock-nejm-2026 (very high)
- Levosimendan VA-ECMO weaning: failed dedicated weaning RCT (primary endpoint); one large cohort (n=200) also showed no benefit; multiple smaller studies and meta-analyses reported benefit — evidence remains conflicting; routine use for weaning is not supported
- Levosimendan VT: REVIVE showed higher VT vs placebo; SURVIVE showed similar rates vs dobutamine — ventricular arrhythmia risk uncertain but lower than catecholamines; contradicts the fully "non-arrhythmogenic" framing of earlier data
- Epinephrine lactic acidosis: metabolic acidosis from epinephrine can mask true shock severity and confound monitoring — avoid where alternatives exist
Connections
- Related to concepts/Cardiogenic-Shock
- Related to concepts/SCAI-Shock-Classification
- Related to concepts/Temporary-Mechanical-Circulatory-Support
- Related to concepts/ECPELLA
- Related to concepts/Invasive-Hemodynamic-Monitoring-CS